Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918239 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
NCT03918239 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 190 participants.
The verdict
NCT03918239, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
Interventions
- DRUG SHP643
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918239
The ClinicalTrials.gov registry entry for NCT03918239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SHP643 is the first listed.
NCT03918239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03918239 about?
NCT03918239 is a clinical study titled "A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.". The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
What is the current status of trial NCT03918239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2019-05-14. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT03918239?
The interventions under investigation include: SHP643 (DRUG).
Who is sponsoring clinical trial NCT03918239?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.